Journal
MARINE DRUGS
Volume 15, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/md15030081
Keywords
chronic obstructive pulmonary disease; comorbidities; management strategy; marine compound; metabolic disorder; inflammation; systems approaches
Categories
Ask authors/readers for more resources
Metabolic disorder has been frequently observed in chronic obstructive pulmonary disease (COPD) patients. However, the exact correlation between obesity, which is a complex metabolic disorder, and COPD remains controversial. The current study summarizes a variety of drugs from marine sources that have anti-obesity effects and proposed potential mechanisms by which lung function can be modulated with the anti-obesity activity. Considering the similar mechanism, such as inflammation, shared between obesity and COPD, the study suggests that marine derivatives that act on the adipose tissues to reduce inflammation may provide beneficial therapeutic effects in COPD subjects with high body mass index (BMI).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available